Direct answer
The C-peptide test measures C-peptide, a fragment released in equal amounts to insulin when the pancreas makes insulin. The C-peptide test therefore estimates how much insulin your own body is producing, including in people already taking insulin injections. Results must be interpreted alongside blood glucose at the same moment, clinical history and other tests.
Key takeaways
- What it shows: The C-peptide test reflects your own (endogenous) insulin production, not injected insulin.
- Why it matters: C-peptide helps clarify diabetes type when the picture is uncertain, and helps investigate low blood sugar.
- Timing is everything: A C-peptide value means little without a paired glucose taken from the same sample.
- It does not label your diabetes on its own: Overlap between type 1, type 2, MODY and ketosis-prone diabetes is real, and antibody tests and genetic testing are often needed.
- It is not a diabetes screening test: Diagnosis of diabetes uses glucose and HbA1c (reported in % NGSP and mmol/mol IFCC), not C-peptide.
At a glance
| Item | Detail |
|---|---|
| What is measured | C-peptide (connecting peptide) in blood, urine, or occasionally after stimulation |
| Sample | Venous blood sample; or timed/24-hour urine; stimulated test uses glucagon or a mixed meal |
| Fasting | Depends on the version ordered and on your unit's protocol, follow the instruction slip you are given |
| Time for blood draw | Usually about 5-10 minutes in the sampling room |
| Time for stimulated test | Commonly 1-3 hours in the department, as repeat samples are taken |
| Time for urine collection | 24 hours of collection at home, then sample submission |
| Paired test | Simultaneous plasma glucose; often insulin, and sometimes diabetes autoantibodies |
| Discomfort | Brief needle prick; bruising possible |
Also known as
- C-peptide, serum
- Connecting peptide insulin test
- Insulin C-peptide test
- Fasting C-peptide / random C-peptide / stimulated C-peptide
- Urinary C-peptide creatinine ratio (UCPCR)
- Commonly asked for in Indian labs as "C peptide test for diabetes type" or, loosely, "pancreas insulin test", this is not the same as the "3 month sugar test" (HbA1c)
What the C-peptide test is
Insulin is first made as a larger molecule called proinsulin. When beta cells in the pancreas process proinsulin, they release insulin and C-peptide together in roughly equal molar amounts. Insulin is largely cleared by the liver on its first pass, while C-peptide is cleared more slowly by the kidneys. That makes C-peptide a steadier marker of how much insulin the pancreas itself is secreting.
Crucially, injected insulin does not contain C-peptide. So in someone on insulin therapy, the C-peptide test can still show whether the pancreas is contributing insulin of its own.
Why the C-peptide test is done
- Clarifying diabetes type: When it is unclear whether a person has type 1, type 2, or another form of diabetes, C-peptide adds information about remaining beta-cell function.
- Investigating unexplained low blood sugar (hypoglycaemia): C-peptide, insulin, glucose and related markers are interpreted together to separate an insulin-secreting tumour or sulfonylurea effect from surreptitious or accidental insulin administration.
- Assessing beta-cell reserve: In long-standing diabetes, to judge how much insulin production remains, which may influence treatment choices.
- After pancreatic surgery or islet/pancreas transplantation: To monitor graft or residual pancreatic function.
- Supporting suspicion of monogenic diabetes (MODY): Preserved C-peptide years into insulin treatment, with negative autoantibodies and a strong family history, may prompt genetic testing.
Who should get this test
- People whose diabetes type is genuinely in doubt, for example, a lean young adult labelled type 2, or an adult with a type 1-like presentation.
- Adults with suspected slowly progressive autoimmune diabetes in adults, usually alongside GAD antibodies.
- People with diabetes on insulin being considered for a change in treatment strategy, where beta-cell reserve is relevant.
- Anyone with documented, recurrent hypoglycaemia that is not explained by their prescribed medicines.
- People with a strong multi-generational family history of diabetes diagnosed young, where MODY is being considered.
- People after pancreatic resection, severe pancreatitis, or transplantation.
The C-peptide test is not appropriate as a general health-check add-on, and it does not diagnose or screen for diabetes.
What the C-peptide test cannot detect or exclude
- It does not diagnose diabetes. Diabetes is diagnosed with fasting plasma glucose, a 75 g oral glucose tolerance test, or HbA1c.
- It does not, by itself, determine diabetes type. Values overlap substantially between type 1, type 2, MODY and ketosis-prone diabetes, especially early after diagnosis when residual beta-cell function may persist in type 1 diabetes.
- It does not measure insulin resistance. A raised C-peptide is consistent with insulin resistance but is not a measurement of it.
- It does not detect pancreatic cancer. Most pancreatic cancers do not secrete insulin. A normal C-peptide does not exclude pancreatic cancer or any pancreatic mass.
- It does not locate an insulinoma. Biochemistry may raise suspicion; localisation needs imaging and specialist assessment.
- A low value does not exclude some remaining beta-cell function, and a normal value does not exclude autoimmune diabetes.
- It does not assess diabetes control. Use glucose monitoring and HbA1c for that.
- It does not exclude adrenal disease. C-peptide is not a test for Addison's disease; adrenal assessment requires cortisol-based testing.
A result described as "not raised" or "within range" describes what the sample showed at that moment. It is not the same as a condition being excluded. If symptoms continue despite a normal or reassuring C-peptide result, go back to the doctor who ordered the test.
Related but different examinations
| Test | Question it answers | How it differs from C-peptide |
|---|---|---|
| Fasting plasma glucose / OGTT | Is blood glucose abnormal? Is diabetes present? | Diagnostic for diabetes; C-peptide is not |
| HbA1c ("3 month sugar test") | What has average glucose been over roughly 2-3 months? | Reflects control over time; C-peptide is a snapshot of insulin secretion |
| Serum insulin | How much insulin is in the circulation right now? | Cannot distinguish injected from self-made insulin; affected by liver clearance and by anti-insulin antibodies |
| Diabetes autoantibodies (GAD65, IA-2, ZnT8, islet cell) | Is there autoimmune destruction of beta cells? | Tests cause; C-peptide tests remaining function. Often ordered together |
| Fasting vs random vs stimulated C-peptide | Baseline secretion vs secretion at an unknown glucose level vs maximal reserve after glucagon or a mixed meal | Different protocols, different interpretation; a random value is uninterpretable without paired glucose |
| Urinary C-peptide creatinine ratio (UCPCR) | Integrated secretion over a period, without a clinic blood draw | Urine-based, needs reliable collection, and is unreliable in significant kidney impairment |
| Genetic testing for MODY | Is there a single-gene cause? | Definitive for monogenic diabetes; C-peptide only helps select who to test |
| Prolonged supervised fast / insulinoma workup | Is there inappropriate insulin secretion during true hypoglycaemia? | A structured inpatient protocol; a single outpatient C-peptide cannot replace it |
No single test is universally "better". Which comes first depends entirely on the clinical problem: for suspected diabetes it is glucose and HbA1c; for suspected autoimmune diabetes it is usually autoantibodies with C-peptide; for unexplained hypoglycaemia it is paired samples drawn during a documented low.
How to prepare
Preparation depends on which version of the C-peptide test has been ordered and on the laboratory's own protocol. Fasting duration, whether water is allowed, sample timing and stimulation agents differ between units. The written instructions given by your collection centre or treating team take precedence over any general advice here.
- Confirm the version: Ask whether the request is fasting, random, stimulated, or urinary C-peptide.
- Medicine list: Bring a full list, including insulin, sulfonylureas (glimepiride, gliclazide), steroids, and any AYUSH, herbal or gym supplements. Do not stop or delay any prescribed medicine yourself, ask the prescriber how to handle doses around the test.
- Alcohol: Avoid alcohol in the day or two before, as it affects glucose handling.
- Urine collection: If a timed or 24-hour collection is requested, follow the container, preservative and refrigeration instructions exactly; an incomplete collection makes the result meaningless.
- Carry glucose: If you are on insulin or a sulfonylurea, carry a sugar source in case of a low while fasting or waiting.
Diabetes on insulin or glucose-lowering tablets
Prolonged fasting carries a real risk of hypoglycaemia on insulin, sulfonylureas or meglitinides. Get explicit instructions from your prescriber about dose timing before a fasting or stimulated test, and about how to test your sugar while waiting.
Chronic kidney disease
C-peptide is cleared by the kidneys, so reduced kidney function raises levels independently of insulin secretion. Urinary C-peptide is not reliable in significant CKD. Tell the laboratory and your doctor about your kidney function.
Pregnancy
Insulin sensitivity changes markedly across pregnancy, and C-peptide interpretation must account for gestation. Prolonged fasting is generally avoided in pregnancy. Gestational diabetes is diagnosed by glucose testing, not C-peptide.
Children
Children tolerate fasting poorly and are more prone to hypoglycaemia. Paediatric endocrinology input is preferred, and stimulated testing in children should be done under supervision.
Older adults and people with heart failure or fluid restriction
Long waits without food or fluids may not be advisable. Where a protocol involves drinking a set volume of fluid, anyone with heart failure, advanced CKD or a prescribed fluid restriction must have this cleared with the treating doctor first.
What happens during the test
- Blood sample: A vein in the arm is cleaned, a tourniquet applied and a sample drawn. The drawing itself takes a couple of minutes; the whole visit for a simple fasting sample is usually around 5-10 minutes plus waiting time. A paired glucose sample is drawn at the same time.
- Stimulated test: A baseline sample is taken, then glucagon is injected or a mixed meal given, followed by samples at set intervals. Expect to stay roughly 1-3 hours depending on the protocol. Nausea and brief vomiting can occur after glucagon.
- Urine test: Collection happens at home over the specified period. For UCPCR, a spot sample is usually taken at a defined time after a meal, following the unit's instruction.
Understanding your report
C-peptide is reported in ng/mL or in nmol/L, and different laboratories use different assays and different reference intervals. Always read your value against the reference range printed on your own report, and do not compare it with a range from another lab or website. Reference ranges also differ for fasting, random and stimulated samples.
What makes a C-peptide result interpretable is context:
- The paired glucose. A "low-normal" C-peptide is expected when glucose is low, and is worrying when glucose is high. A "normal" C-peptide during documented hypoglycaemia is abnormal, because secretion should have shut down.
- Duration of diabetes. Preserved C-peptide in the first year or two of type 1 diabetes is common and does not rule it out.
- Kidney function, which slows clearance and raises values.
- Current treatment, particularly insulin, sulfonylureas and steroids.
Broadly, a higher C-peptide suggests the pancreas is secreting plenty of insulin, seen with insulin resistance, type 2 diabetes, obesity, PCOS (PCOS and "PCOD" refer to the same condition), insulinoma, sulfonylurea use and reduced renal clearance. A lower C-peptide suggests limited insulin secretion, seen in type 1 diabetes, long-standing type 2 diabetes with beta-cell decline, after pancreatic surgery or severe pancreatic disease, and during hypoglycaemia caused by injected insulin. These are patterns, not diagnoses. Results vary depending on individual clinical circumstances, and only the doctor who requested the test can interpret them for you.
When results can be misleading
Falsely raised or higher than expected
- Reduced kidney function: Slower clearance raises C-peptide without any change in secretion. This is the commonest reason for a misleadingly high value.
- Recent food or glucose load: A non-fasting sample naturally shows higher C-peptide.
- Sulfonylureas and meglitinides: These drugs stimulate insulin secretion, so C-peptide rises. In hypoglycaemia workup this can mimic an insulinoma; a drug screen may be needed.
- Corticosteroids and other drugs that raise glucose: Secondary rise in insulin secretion.
- Assay interference: Heterophile antibodies or biotin (high-dose supplements) can affect some immunoassays. Mention any supplements.
Falsely lowered or lower than expected
- Sampling during hypoglycaemia or after a prolonged fast: Appropriate suppression may be misread as beta-cell failure.
- Acute severe hyperglycaemia or glucose toxicity: Temporarily suppresses secretion; a very low value at presentation may improve after glucose is stabilised, so repeat testing is often advised.
- Sample handling problems: Delayed separation or improper storage can degrade C-peptide.
- Incomplete urine collection: Under-collection falsely lowers urinary results.
- Acute illness, surgery or major stress: Can shift values in either direction.
Risks and safety
Simple blood sample
Risks are small and mostly local: brief pain, bruising, light-headedness, and rarely a small haematoma or infection at the puncture site. People on blood thinners should press the site for longer.
Urine collection
No physical risk. The main issue is an inaccurate result from incomplete or mishandled collection.
Glucagon-stimulated test
Additional considerations apply. Nausea, vomiting, abdominal discomfort, headache and a transient rise in blood pressure and glucose can occur. Glucagon needs caution in people with phaeochromocytoma, insulinoma, significant cardiac disease, or depleted liver glycogen stores. This version should be done in a supervised setting after a doctor has reviewed suitability.
Mixed-meal tolerance test
Generally well tolerated, but the meal raises glucose, so people with diabetes need a plan for monitoring and for insulin dosing around the test.
Red flags
Emergency now
- Confusion, seizure, slurred speech, or inability to be roused, possible severe hypoglycaemia. Give sugar if the person can swallow safely and get emergency help.
- Vomiting with deep rapid breathing, abdominal pain, drowsiness and very high sugars, possible diabetic ketoacidosis.
- Collapse, chest pain or breathlessness during or after a stimulation test.
Same day
- Repeated hypoglycaemic episodes, or lows you can no longer feel coming.
- Sustained high sugars with ketones on a home or urine test.
- Marked spreading swelling, redness or fever at the blood-draw site.
- New rapid weight loss with heavy thirst and frequent urination.
Routine appointment
- Discussing a C-peptide result and what it means for your treatment.
- Occasional mild lows that respond quickly to sugar.
- Persistent bruising or tenderness at the puncture site that is settling.
- Symptoms that continue despite a normal result.
Special situations
Pregnancy
C-peptide has a limited role in pregnancy and is not used to diagnose gestational diabetes. Where it is ordered, interpretation must allow for the physiological insulin resistance of later pregnancy.
Children and adolescents
Most children presenting with diabetes in India have type 1 diabetes, but type 2 diabetes and MODY do occur. C-peptide with autoantibodies helps, though early in type 1 diabetes C-peptide may still be preserved. Paediatric specialist interpretation is important.
Older adults
Coexisting kidney impairment is common and raises C-peptide. Fasting protocols may need shortening.
Diabetes on insulin or sulfonylureas
C-peptide is one of the few tests that can distinguish your own insulin from injected insulin. Do not adjust your doses for the test without instruction from your prescriber.
Chronic kidney disease and dialysis
Blood C-peptide is usually elevated and harder to interpret; urinary C-peptide is not recommended. Nephrology and endocrinology input helps.
Heart failure or fluid restriction
Any protocol requiring fasting plus fluid loading should be reviewed by the treating doctor before the appointment.
After pancreatitis or pancreatic surgery
C-peptide helps gauge remaining beta-cell function in post-pancreatectomy or pancreatogenic diabetes, which often needs insulin and has a higher hypoglycaemia risk.
The C-peptide test in the Indian context
- Metabolic disease at lower BMI: South Asians commonly develop insulin resistance and type 2 diabetes at a lower body mass index and younger age than many other populations. A lean build alone is therefore a weak argument against type 2 diabetes, and C-peptide with autoantibodies is often more useful than body habitus for sorting out type.
- Type labelling errors are common: Young adults are sometimes started on insulin and labelled type 1 without antibody or C-peptide testing. Preserved C-peptide years later, with negative antibodies and a strong family history, should prompt reconsideration, including MODY.
- Pancreatogenic diabetes: Chronic calcific pancreatitis, including tropical forms reported in parts of India, can cause diabetes with low C-peptide.
- Supplements and herbal products: Widely used gym and AYUSH products may contain undeclared glucose-lowering or steroid-like ingredients that alter insulin secretion. Declare everything you take.
- Sulfonylurea availability: Glimepiride and gliclazide are prescribed widely and are a frequent cause of hypoglycaemia with a raised C-peptide, a pattern easily mistaken for insulinoma unless drug history is checked.
- HbA1c interpretation alongside: Where HbA1c is used in parallel, remember that thalassaemia trait, other haemoglobinopathies and iron-deficiency anaemia, all common in India, can distort HbA1c. Glucose-based testing may be more dependable in those people.
- Terminology: Requests may be written as "C peptide (fasting)", "C peptide random" or simply "C-peptide". Confirm which was intended before fasting overnight unnecessarily.
Cost and insurance, and what affects cost in India
Pricing for a C-peptide test differs considerably between cities, between public and private laboratories, and between a single blood sample and a stimulated protocol. Quoted amounts change over time, so ask the laboratory for a current, itemised quote before booking rather than relying on a published figure.
Factors that move the price:
- Version ordered: a single fasting sample costs less than a stimulated test with serial samples, or a 24-hour urine collection.
- Add-on tests: paired glucose, insulin, GAD and other autoantibodies, and kidney function each add cost. Genetic testing for MODY is substantially more expensive.
- Assay and accreditation: laboratory accreditation status and whether the assay is run in-house or referred out.
- Setting: outpatient versus inpatient, day-care charges for supervised stimulation tests, and home-collection fees.
- City and sector: metro private labs typically differ from government and trust hospitals.
On insurance: outpatient investigations are often not covered under standard indemnity health policies in India, while the same test done during an admissible hospitalisation is more likely to be reimbursed. Coverage also depends on OPD riders, corporate plans and government schemes. Check with your insurer or the hospital's insurance desk with the exact test name before the test, and keep the doctor's prescription showing medical indication.
Myths and facts
| Myth | Fact |
|---|---|
| A C-peptide test can tell me whether I have diabetes | Diabetes is diagnosed with glucose testing or HbA1c. C-peptide describes insulin production, not whether diabetes is present |
| A low C-peptide means type 1 diabetes | Low values also occur in long-standing type 2 diabetes, after pancreatic disease or surgery, and transiently during severe hyperglycaemia |
| A normal C-peptide means I do not have type 1 diabetes | C-peptide can be preserved for months to years after a type 1 diagnosis. Autoantibody testing and clinical course matter |
| A high C-peptide means I have a pancreatic tumour | Far more often it reflects insulin resistance, a recent meal, sulfonylurea therapy or reduced kidney clearance |
| C-peptide can screen for pancreatic cancer | It cannot. Most pancreatic cancers do not secrete insulin, and a normal value does not exclude any pancreatic disease |
| A raised C-peptide means insulin injections are unnecessary | Treatment decisions depend on glucose control, symptoms and overall assessment. Never change insulin on the basis of a single result |
| "PCOD" is different from PCOS, and each affects C-peptide differently | PCOD and PCOS are the same condition. Associated insulin resistance can raise C-peptide |
Frequently asked questions
What is the purpose of a C-peptide test?
The C-peptide test estimates how much insulin your own pancreas is secreting. Clinicians use the C-peptide test mainly to clarify diabetes type when the picture is uncertain, to judge remaining beta-cell function, and to help investigate repeated unexplained low blood sugar. It is not used to diagnose or screen for diabetes.
Do I need to fast before a C-peptide test?
It depends on which version has been ordered. Fasting samples, random samples and stimulated protocols each have different instructions, and fasting durations vary between laboratories. Follow the written instruction from your collection centre. If you take insulin or a sulfonylurea, ask your prescriber how to manage doses before fasting.
How long does the whole process take?
A simple blood draw usually takes about five to ten minutes, plus registration and waiting. A glucagon-stimulated or mixed-meal C-peptide test typically keeps you in the department for roughly one to three hours because samples are taken at intervals. A 24-hour urine collection runs over a full day at home.
Why is a glucose sample taken at the same time?
Because a C-peptide value on its own is hard to interpret. The same number can be normal or clearly abnormal depending on the blood glucose at that instant. During true hypoglycaemia, insulin secretion should switch off, so a mid-range C-peptide in that setting is an important abnormal finding.
Can medicines or supplements change the result?
Yes. Sulfonylureas and meglitinides increase insulin secretion and raise C-peptide. Steroids can raise it indirectly. High-dose biotin supplements may interfere with some assays. Herbal, AYUSH and gym products sometimes contain undeclared active ingredients. List everything you take, and do not stop prescribed medicines on your own.
Does kidney disease affect C-peptide?
Yes, importantly. C-peptide is cleared by the kidneys, so impaired kidney function raises blood levels even when insulin secretion is unchanged. That can create a falsely reassuring or falsely high picture. Urinary C-peptide measurement is unreliable in significant chronic kidney disease and is usually avoided there.
How is C-peptide different from an insulin test?
Serum insulin measures insulin in the circulation and cannot separate injected insulin from your own. C-peptide is released only by your pancreas, is not present in insulin injections, and is cleared more slowly, so it gives a steadier picture of your own secretion. The two tests are often ordered together.
Will one C-peptide result decide my diabetes treatment?
No. A single value is a snapshot influenced by glucose level, recent illness, kidney function and medication. Doctors usually interpret C-peptide together with autoantibodies, duration of diabetes, glucose patterns and sometimes repeat or stimulated testing. Results vary depending on individual clinical circumstances and require review by the doctor who ordered the test.
My C-peptide was normal but my symptoms continue. What now?
A normal result describes that sample at that moment; it does not exclude disease. Return to the doctor who requested the test. Repeat testing at a better time, paired glucose during symptoms, autoantibody testing, or imaging may be needed depending on what is being investigated.
Sources
- American Diabetes Association, Standards of Care in Diabetes, sections on classification and diagnosis of diabetes.
- Endocrine Society clinical practice guideline on the evaluation and management of adult hypoglycaemic disorders.
- Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine.
- International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines, classification and diagnosis.
- Indian Council of Medical Research, Guidelines for Management of Type 2 Diabetes.
- National Institute for Health and Care Excellence (NICE) guidance on type 1 and type 2 diabetes in adults.
